The University of Queensland

Abstract 4626: Spatial profiling of the tumor microenvironment in head and neck cancer identifies immune checkpoints and proteins involved in cell death signaling biomarkers of immunotherapy response

Sadeghirad, Habib, Liu, Ning, Monkman, James, Tan, Chin Wee, Cooper, Caroline, Caldera, Jeni, Church, Sarah, Schneider, Fabian, Mansfield, James Robert, O'Byrne, Ken, Davis, Melissa, Hughes, Brett and Kulasinghe, Arutha (2023). Abstract 4626: Spatial profiling of the tumor microenvironment in head and neck cancer identifies immune checkpoints and proteins involved in cell death signaling biomarkers of immunotherapy response. Cancer Research, 83 (7_Supplement), 4626-4626. doi: 10.1158/1538-7445.am2023-4626

Abstract 5647: Single cell, multiomic spatial phenotyping of immunotherapy responses in head and neck cancer

Ji, HaYeun, Jhaveri, Niyati, Ma, Ning, Cheikh, Bassem B., Pratapa, Aditya, Monkman, James, O’Byrne, Ken, Hughes, Brett, Kulasinghe, Arutha and Braubach, Oliver (2023). Abstract 5647: Single cell, multiomic spatial phenotyping of immunotherapy responses in head and neck cancer. Cancer Research, 83 (7_Supplement), 5647-5647. doi: 10.1158/1538-7445.am2023-5647

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy

Sadeghirad, Habib, Liu, Ning, Monkman, James, Ma, Ning, Cheikh, Bassem Ben, Jhaveri, Niyati, Tan, Chin Wee, Warkiani, Majid Ebrahimi, Adams, Mark N., Nguyen, Quan, Ladwa, Rahul, Braubach, Oliver, O’Byrne, Ken, Davis, Melissa, Hughes, Brett G. M. and Kulasinghe, Arutha (2023). Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy. Frontiers in Immunology, 14 1135489, 1-16. doi: 10.3389/fimmu.2023.1135489

Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity‐modulated radiotherapy with concurrent chemotherapy

Blake, Claire L., Brown, Teresa E., Pelecanos, Anita, Moroney, Laura B., Helios, Jennifer, Hughes, Brett G. M., Chua, Benjamin and Kenny, Lizbeth M. (2023). Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity‐modulated radiotherapy with concurrent chemotherapy. Head and Neck, 45 (2), 417-430. doi: 10.1002/hed.27249

LOREALAUS: LOrlatinib REAL world AUStralian experience in advanced anaplastic lymphoma kinase rearranged non-small cell lung cancer

Alexander, Marliese, Wei, Joe, Parakh, Sagun, John, Thomas, Kao, Steven, Nagrial, Adnan, Bowyer, Samantha, Warburton, Lydia, Moore, Melissa, Hughes, Brett GM, Clay, Timothy D, Pavlakis, Nick, Solomon, Benjamin J and Itchins, Malinda (2023). LOREALAUS: LOrlatinib REAL world AUStralian experience in advanced anaplastic lymphoma kinase rearranged non-small cell lung cancer. JTO Clinical and Research Reports, 4 (4) 100490, 100490. doi: 10.1016/j.jtocrr.2023.100490

Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day

Taylor, Matthew H., Leboulleux, Sophie, Panaseykin, Yury, Konda, Bhavana, de La Fouchardiere, Christelle, Hughes, Brett G. M., Gianoukakis, Andrew G., Park, Young Joo, Romanov, Ilia, Krzyzanowska, Monika K., Garbinsky, Diana, Sherif, Bintu, Pan, Jie Janice, Binder, Terri A., Sauter, Nicholas, Xie, Ran and Brose, Marcia S. (2022). Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Medicine, 12 (4), 4332-4342. doi: 10.1002/cam4.5308

Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer

Miller, Richard A, Luke, Jason John, Hu, Shenshen, Mahabhashyam, Suresh, Jones, William B, Marron, Thomas, Merchan, Jaime R, Hughes, Brett G M and Willingham, Stephen B (2022). Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. Journal for ImmunoTherapy of Cancer, 10 (12) e005802, e005802. doi: 10.1136/jitc-2022-005802

Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study

Jiang, Yingying, Shi, Yue, Liu, Yiling, Wang, Zihan, Ma, Yuxin, Shi, Xinhong, Lu, Lin, Wang, Zhitong, Li, Hang, Zhang, Yushu, Liu, Caolu, Zhang, Shaorui, Zhong, Zhihao, Lu, Jianwei, Shi, Meiqi, Shen, Bo, Zhou, Guoren, Yin, Rong, Galetta, Domenico, Grenda, Anna, Romero, Atocha, Hughes, Brett G. M., Chen, Cheng, Wang, Xiaohua and Feng, Jifeng (2022). Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study. Translational Lung Cancer Research, 11 (12), 2521-2538. doi: 10.21037/tlcr-22-857

Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 Study

Harrington, Kevin J., Burtness, Barbara, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Brana, Irene, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Lin, Jianxin, Gumuscu, Burak, Swaby, Ramona F. and Rischin, Danny (2022). Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 Study. Journal of Clinical Oncology, 41 (4), 790-802. doi: 10.1200/jco.21.02508

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

Gross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo B., Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G.M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Kaufman, Howard L., Seebach, Frank, Lowy, Israel, Yoo, Suk-Young, Mathias, Melissa, Fenech, Keilah, Han, Hyunsil, Fury, Matthew G. and Rischin, Danny (2022). Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. New England Journal of Medicine, 387 (17), 1557-1568. doi: 10.1056/nejmoa2209813

Prevalence and impact of computed tomography-defined sarcopenia on survival in patients with human papillomavirus-positive oropharyngeal cancer: a systematic review

Edwards, Anna, Hughes, Brett G M, Brown, Teresa and Bauer, Judith (2022). Prevalence and impact of computed tomography-defined sarcopenia on survival in patients with human papillomavirus-positive oropharyngeal cancer: a systematic review. Advances in Nutrition, 13 (6), 2433-2444. doi: 10.1093/advances/nmac076

Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: Subgroup analysis by programmed death ligand-1 combined positive score

Burtness, Barbara, Rischin, Danny, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro Jr, Gilberto, Psyrri, Amanda, Brana, Irene, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Ge, Joy, Swaby, Ramona F., Gumuscu, Burak and Harrington, Kevin (2022). Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: Subgroup analysis by programmed death ligand-1 combined positive score. Journal of Clinical Oncology, 40 (21), 2321-2332. doi: 10.1200/jco.21.02198

Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer

Kapeleris, Joanna, Bark, Juliana Müller, Ranjit, Shanon, Irwin, Darryl, Hartel, Gunter, Warkiani, Majid Ebrahimi, Leo, Paul, O’Leary, Connor, Ladwa, Rahul, O'Byrne, Kenneth, Hughes, Brett G.M. and Punyadeera, Chamindie (2022). Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer. Heliyon, 8 (7) e09971, 1-9. doi: 10.1016/j.heliyon.2022.e09971

Application of circulating tumour cells to predict response to treatment in head and neck cancer

Zhang, Xi, Ekanayake Weeramange, Chameera, Hughes, Brett G. M., Vasani, Sarju, Liu, Zhen Yu, Warkiani, Majid Ebrahimi, Hartel, Gunter, Ladwa, Rahul, Thiery, Jean Paul, Kenny, Liz and Punyadeera, Chamindie (2022). Application of circulating tumour cells to predict response to treatment in head and neck cancer. Cellular Oncology, 45 (4), 1-13. doi: 10.1007/s13402-022-00681-w

A randomized, double-blind noninferiority study to evaluate the efficacy of the cabozantinib tablet at 60 mg per day compared with the cabozantinib capsule at 140 mg per day in patients with progressive, metastatic medullary thyroid cancer

Capdevila, Jaume, Klochikhin, Arkadiy, Leboulleux, Sophie, Isaev, Pavel, Badiu, Corin, Robinson, Bruce, Hughes, Brett G.M., Keam, Bhumsuk, Parnis, Francis, Elisei, Rossella, Gajate, Pablo, Gan, Hui K., Kapiteijn, Ellen, Locati, Laura, Mangeshkar, Milan, Faoro, Leonardo, Krajewska, Jolanta and Jarzab, Barbara (2022). A randomized, double-blind noninferiority study to evaluate the efficacy of the cabozantinib tablet at 60 mg per day compared with the cabozantinib capsule at 140 mg per day in patients with progressive, metastatic medullary thyroid cancer. Thyroid, 32 (5), 515-524. doi: 10.1089/thy.2022.0027

Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas

Sadeghirad, Habib, Monkman, James, Mehdi, Ahmed M., Ladwa, Rahul, O’Byrne, Ken, Hughes, Brett G. M. and Kulasinghe, Arutha (2022). Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas. Frontiers in Immunology, 13 895513, 1-11. doi: 10.3389/fimmu.2022.895513

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048

Rischin, Danny, Harrington, Kevin J., Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro Jr, Gilberto, Psyrri, Amanda, Braña, Irene, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesía, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Hong, Ruey-Long, Mendoza, René Gonzalez, Jia, Liyi, Chirovsky, Diana, Norquist, Josephine, Jin, Fan and Burtness, Barbara (2022). Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncology, 128 105815, 105815. doi: 10.1016/j.oraloncology.2022.105815

The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review

Edwards, Anna, Brown, Teresa, Hughes, Brett G. M. and Bauer, Judy (2022). The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review. Supportive Care in Cancer, 30 (9), 7191-7204. doi: 10.1007/s00520-022-07056-9

A randomized study of Lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer

Brose, Marcia S., Panaseykin, Yury, Konda, Bhavana, de la Fouchardiere, Christelle, Hughes, Brett G. M., Gianoukakis, Andrew G., Joo Park, Young, Romanov, Ilia, Krzyzanowska, Monika K., Leboulleux, Sophie, Binder, Terri A., Dutcus, Corina, Xie, Ran and Taylor, Matthew H. (2022). A randomized study of Lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 107 (3), 776-787. doi: 10.1210/clinem/dgab731

Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment

Ahern, Elizabeth, Brown, Teresa E, Campbell, Louise, Hughes, Brett G. M., Banks, Merrilyn D., Lin, Charles Y., Kenny, Lizbeth M. and Bauer, Judith D. (2022). Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment. British Journal of Nutrition, 129 (3), 1-25. doi: 10.1017/S0007114522000435

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Peters, S., Pujol, J. L., Dafni, U., Dómine, M., Popat, S., Reck, M., Andrade, J., Becker, A., Moro-Sibilot, D., Curioni-Fontecedro, A., Molinier, O., Nackaerts, K., Insa Mollá, A., Gervais, R., López Vivanco, G., Madelaine, J., Mazieres, J., Faehling, M., Griesinger, F., Majem, M., González Larriba, J. L., Provencio Pulla, M., Vervita, K., Roschitzki-Voser, H., Ruepp, B., Mitchell, P., Stahel, R. A., Le Pechoux, C., De Ruysscher, D. ... Califano, R. (2022). Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Annals of Oncology, 33 (1), 67-79. doi: 10.1016/j.annonc.2021.09.011

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial

Kok, Peey Sei, Forde, Patrick M., Hughes, Brett, Sun, Zhuoxin, Brown, Chris, Ramalingam, Suresh, Cook, Alistair, Lesterhuis, Willem Joost, Yip, Sonia, O'Byrne, Ken, Pavlakis, Nick, Brahmer, Julie, Anagnostou, Valsamo, Ford, Kate, Fitzpatrick, Karen, Bricker, Alison, Cummins, Michelle M., Stockler, Martin and Nowak, Anna K. (2022). Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial. BMJ Open, 12 (1) e057663, e057663. doi: 10.1136/bmjopen-2021-057663

Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008))

Hughes, B. G.M., Munoz-Couselo, E., Mortier, L., Bratland, , Gutzmer, R., Roshdy, O., González Mendoza, R., Schachter, J., Arance, A., Grange, F., Meyer, N., Joshi, A., Billan, S., Zhang, P., Gumuscu, B., Swaby, R. F. and Grob, J. J. (2022). Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008)). Annals of Oncology, 33 (8), 853-853. doi: 10.1016/j.annonc.2022.05.517

Understanding the tumor microenvironment in head and neck squamous cell carcinoma

Rad, Habib Sadeghi, Shiravand, Yavar, Radfar, Payar, Ladwa, Rahul, Perry, Chris, Han, Xiaoyuan, Warkiani, Majid Ebrahimi, Adams, Mark N., Hughes, Brett G.M., O'Byrne, Ken and Kulasinghe, Arutha (2022). Understanding the tumor microenvironment in head and neck squamous cell carcinoma. Clinical & Translational Immunology, 11 (6) e1397, e1397. doi: 10.1002/cti2.1397

Evaluation of a novel pre‐treatment model of nutrition care for patients with head and neck cancer receiving chemoradiotherapy

Blake, Claire, Edwards, Anna, Treleaven, Elise, Brown, Teresa, Hughes, Brett, Lin, Charles, Kenny, Lizbeth, Banks, Merrilyn and Bauer, Judy (2021). Evaluation of a novel pre‐treatment model of nutrition care for patients with head and neck cancer receiving chemoradiotherapy. Nutrition and Dietetics, 79 (2), 206-216. doi: 10.1111/1747-0080.12714

A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma

Lin, Charles, Ballah, Trishna, Nottage, Michelle, Hay, Karen, Chua, Benjamin, Kenny, Lizbeth, Thomas, Paul, Teng, Michele, Keller, Jacqui, Le, Trang, Edmunds, Jennifer and Hughes, Brett (2021). A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma. Radiation Oncology, 16 (1) 69, 1-13. doi: 10.1186/s13014-021-01795-5

Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study

Rischin, Danny, King, Madeleine, Kenny, Lizbeth, Porceddu, Sandro, Wratten, Christopher, Macann, Andrew, Jackson, James E., Bressel, Mathias, Herschtal, Alan, Fisher, Richard, Fua, Tsien, Lin, Charles, Liu, Chen, Hughes, Brett G.M., McGrath, Margaret, McDowell, Lachlan and Corry, June (2021). Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study. International Journal of Radiation: Oncology - Biology - Physics, 111 (4), 876-886. doi: 10.1016/j.ijrobp.2021.04.015

The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC)

Kulasinghe, Arutha, O'Leary, Connor, Monkman, James, Bharti, Vandhana, Irwin, Darryl, Dutta, Sanjay, Richard, Derek J., Hughes, Brett, Ladwa, Rahul and O'Byrne, Ken (2021). The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC). Lung Cancer, 160, 73-77. doi: 10.1016/j.lungcan.2021.08.005

Health-related quality of life of patients with recurrent or metastatic cutaneous squamous cell carcinoma treated with Pembrolizumab in KEYNOTE-629

Hughes, Brett G. M., Mendoza, Rene Gonzalez, Basset-Seguin, Nicole, Vornicova, Olga, Schachter, Jacob, Joshi, Abhishek, Meyer, Nicolas, Grange, Florent, Piulats, Josep M., Bauman, Jessica R., Chirovsky, Diana, Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F. and Grob, Jean-Jacques (2021). Health-related quality of life of patients with recurrent or metastatic cutaneous squamous cell carcinoma treated with Pembrolizumab in KEYNOTE-629. Dermatology and Therapy, 11 (5), 1777-1790. doi: 10.1007/s13555-021-00598-6

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

Rischin, Danny, Khushalani, Nikhil I., Schmults, Chrysalyne D., Guminski, Alexander, Chang, Anne Lynn S., Lewis, Karl D., Lim, Annette M., Hernandez-Aya, Leonel, Hughes, Brett G. M., Schadendorf, DIrk, Hauschild, Axel, Thai, Alesha A., Stankevich, Elizabeth, Booth, Jocelyn, Yoo, Suk-Young, Li, Siyu, Chen, Zhen, Okoye, Emmanuel, Chen, Chieh-I, Mastey, Vera, Sasane, Medha, Lowy, Israel, Fury, Matthew G. and Migden, Michael R. (2021). Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. Journal for ImmunoTherapy of Cancer, 9 (8) e002757, e002757. doi: 10.1136/jitc-2021-002757

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

Hughes, B. G. M., Munoz-Couselo, E., Mortier, L., Bratland, Å., Gutzmer, R., Roshdy, O., González Mendoza, R., Schachter, J., Arance, A., Grange, F., Meyer, N., Joshi, A., Billan, S., Zhang, P., Gumuscu, B., Swaby, R. F. and Grob, J.-J. (2021). Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Annals of Oncology, 32 (10), 1276-1285. doi: 10.1016/j.annonc.2021.07.008

Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time?

Ahern, Elizabeth, Solomon, Ben J, Hui, Rina, Pavlakis, Nick, O'Byrne, Ken and Hughes, Brett G M (2021). Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time?. Journal for ImmunoTherapy of Cancer, 9 (6) e002248, e002248. doi: 10.1136/jitc-2020-002248

Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes

Reynolds, K. A., Schlessinger, D. I., Yanes, A. F., Godinez-Puig, V., Chen, B. R., Kurta, A. O., Cotseones, J. K., Chiren, S. G., Iyengar, S., Ibrahim, S. A., Kang, B. Y., Worley, B., Behshad, R., DeHoratius, D. M., Denes, P., Drucker, A. M., Dzubow, L. M., Etzkorn, J. R., Harwood, C. A., Kim, J. Y. S., Lawrence, N., Lee, E. H., Lissner, G. S., Marghoob, A. A., Guminiski, A., Matin, R. N., Mattox, A. R., Mittal, B. B., Thomas, J. R. ... Alam, M. (2021). Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes. British Journal of Dermatology, 184 (6), 1113-1122. doi: 10.1111/bjd.19693

EGFR exon 20 insertion mutations: clinicopathological characteristics and treatment outcomes in advanced non–small cell lung cancer

Leal, Jose Luis, Alexander, Marliese, Itchins, Malinda, Wright, Gavin M., Kao, Steven, Hughes, Brett G.M., Pavlakis, Nick, Clarke, Stephen, Gill, Anthony J, Ainsworth, Hannah, Solomon, Benjamin and John, Thomas (2021). EGFR exon 20 insertion mutations: clinicopathological characteristics and treatment outcomes in advanced non–small cell lung cancer. Clinical Lung Cancer, 22 (6), e859-e869. doi: 10.1016/j.cllc.2021.04.009

Semiqualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, Australia

Gasper, Harry, Ahern, Elizabeth, Roberts, Natasha, Chan, Bryan, Hughes, Brett, Kennedy, Glen, Wyld, David, Eastgate, Melissa and Lwin, Zarnie (2021). Semiqualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, Australia. BMJ Open, 11 (5) e044655, e044655. doi: 10.1136/bmjopen-2020-044655

Highly multiplexed digital spatial profiling of the tumor microenvironment of head and neck squamous cell carcinoma patients

Kulasinghe, Arutha, Taheri, Touraj, O'Byrne, Ken, Hughes, Brett G. M., Kenny, Liz and Punyadeera, Chamindie (2021). Highly multiplexed digital spatial profiling of the tumor microenvironment of head and neck squamous cell carcinoma patients. Frontiers in Oncology, 10 607349, 607349. doi: 10.3389/fonc.2020.607349

CCTG BR34: a randomized phase 2 trial of Durvalumab and Tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLC

Leighl, Natasha B., Laurie, Scott A., Goss, Glenwood D., Hughes, Brett G.M., Stockler, Martin, Tsao, Ming-Sound, Hwang, David M., Joubert, Phillipe, Kulkarni, Swati, Blais, Normand, Joy, Anil A., Mates, Mihaela, Rana, Punam, Yadav, Sunil K., Underhill, Craig, Lee, Christopher, Bradbury, Penelope A., Hiltz, Andrea, Dancey, Janet, Ding, Keyue and Vera-Badillo, Francisco (2021). CCTG BR34: a randomized phase 2 trial of Durvalumab and Tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLC. Journal of Thoracic Oncology, 17 (3), 434-445. doi: 10.1016/j.jtho.2021.10.023

CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells

Braun, Matthias, Aguilera, Amelia Roman, Sundarrajan, Ashmitha, Corvino, Dillon, Stannard, Kimberley, Krumeich, Sophie, Das, Indrajit, Lima, Luize G., Meza Guzman, Lizeth G., Li, Kunlun, Li, Rui, Salim, Nazhifah, Jorge, Maria Villancanas, Ham, Sunyoung, Kelly, Gabrielle, Vari, Frank, Lepletier, Ailin, Raghavendra, Ashwini, Pearson, Sally, Madore, Jason, Jacquelin, Sebastien, Effern, Maike, Quine, Brodie, Koufariotis, Lambros T., Casey, Mika, Nakamura, Kyohei, Seo, Eun Y., Hölzel, Michael, Geyer, Matthias ... Bald, Tobias (2020). CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells. Immunity, 53 (4), 805-823.e15. doi: 10.1016/j.immuni.2020.09.010

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Nowak, Anna K, Lesterhuis, W Joost, Kok, Peey-Sei, Brown, Chris, Hughes, Brett GM, Karikios, Deme J, John, Thomas, Kao, Steven C-H, Leslie, Connull, Cook, Alistair M, Pavlakis, Nick, Briscoe, Karen, O'Byrne, Kenneth J, Karapetis, Christos S, Lam, Wei-Sen, Langford, Ailsa, Yip, Sonia and Stockler, Martin R (2020). Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology, 21 (9), 1213-1223. doi: 10.1016/S1470-2045(20)30462-9

Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma

Tang, Kai D., Vasani, Sarju, Menezes, Lilian, Taheri, Touraj, Walsh, Laurence J., Hughes, Brett G.M., Frazer, Ian H., Kenny, Liz, Scheper, Gert C. and Punyadeera, Chamindie (2020). Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma. Cancer Science, 111 (10) cas.14585, 3854-3861. doi: 10.1111/cas.14585

Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE)

Ahern, Elizabeth, Allen, Michael J., Schmidt, Andrew, Lwin, Zarnie and Hughes, Brett G. M. (2020). Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE). Asia-Pacific Journal of Clinical Oncology, 17 (2) ajco.13350, e109-e116. doi: 10.1111/ajco.13350

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412

Machiels, Jean-Pascal, Tao, Yungan, Burtness, Barbara, Tahara, Makoto, Licitra, Lisa, Rischin, Danny, Waldron, John, Simon, Christian, Gregoire, Vincent, Harrington, Kevin, Alves, Gustavo Vasconcelos, Figueiredo Lima, Iane Pinto, Pointreau, Yoann, M Hughes, Brett G., Aksoy, Sercan, Hetnal, Marcin, Ge, Joy Y., Brown, Holly, Cheng, Jonathan, Bidadi, Behzad and Siu, Lillian L. (2020). Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Future oncology (London, England), 16 (18), 1235-1243. doi: 10.2217/fon-2020-0184

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Rischin, Danny, Migden, Michael R., Lim, Annette M., Schmults, Chrysalyne D., Khushalani, Nikhil I., Hughes, Brett G. M., Schadendorf, Dirk, Dunn, Lara A., Hernandez-Aya, Leonel, Chang, Anne Lynn S., Modi, Badri, Hauschild, Axel and Ulrich, Claas (2020). Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. Journal for immunotherapy of cancer, 8 (1) e000775. doi: 10.1136/jitc-2020-000775

A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer

Alexander, Marliese, Pavlakis, Nick, John, Thomas, O'Connell, Rachel, Kao, Steven, Hughes, Brett G.M., Lee, Adrian, Hayes, Sarah A., Howell, Viive M., Clarke, Stephen J., Millward, Michael, Burbury, Kate, Solomon, Benjamin and Itchins, Malinda (2020). A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. Lung Cancer, 142, 34-40. doi: 10.1016/j.lungcan.2020.01.017

Weighted activity unit effect: evaluating the cost of diagnosis-related group coding

Tan, Joanne Y.-A., Senko, Clare, Hughes, Brett, Lwin, Zarnie, Bennett, Richard, Power, John and Thomson, Leah (2020). Weighted activity unit effect: evaluating the cost of diagnosis-related group coding. Internal Medicine Journal, 50 (4), 440-444. doi: 10.1111/imj.14373

An occult HPV-driven oropharyngeal squamous cell carcinoma discovered through a saliva test

Tang, Kai Dun, Vasani, Sarju, Taheri, Touraj, Walsh, Laurence J., Hughes, Brett G. M., Kenny, Lizbeth and Punyadeera, Chamindie (2020). An occult HPV-driven oropharyngeal squamous cell carcinoma discovered through a saliva test. Frontiers in Oncology, 10 408, 408. doi: 10.3389/fonc.2020.00408

Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer

Ratnayake, Gishan, Shanker, Mihir, Roberts, Kate, Mason, Robert, Hughes, Brett G. M., Lwin, Zarnie, Jain, Vikram, O'Byrne, Kenneth, Lehman, Margot and Chua, Benjamin (2020). Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 16 (1), 56-62. doi: 10.1111/ajco.13242

Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer

Fong, Lawrence, Hotson, Andrew, Powderly, John D., Sznol, Mario, Heist, Rebecca S., Choueiri, Toni K., George, Saby, Hughes, Brett G. M., Hellmann, Matthew D., Shepard, Dale R., Rini, Brian I., Kummar, Shivaani, Weise, Amy M., Riese, Matthew J., Markman, Ben, Emens, Leisha A., Mahadevan, Daruka, Luke, Jason J., Laport, Ginna, Brody, Joshua D., Hernandez-Aya, Leonel, Bonomi, Philip, Goldman, Jonathan W., Berim, Lyudmyla, Renouf, Daniel J., Goodwin, Rachel A., Munneke, Brian, Ho, Po Y., Hsieh, Jessica ... Miller, Richard A. (2020). Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer. Cancer Discovery, 10 (1), 40-53. doi: 10.1158/2159-8290.CD-19-0980

Outcomes of incidental pulmonary nodules in head-and-neck squamous cell cancer patients treated with curative intent

Tani, Daniel, Ladwa, Rahul, Xu, Wen, Lwin, Zarnie, Steinke, Karin and Hughes, Brett G. M. (2020). Outcomes of incidental pulmonary nodules in head-and-neck squamous cell cancer patients treated with curative intent. Journal of Head and Neck Physicians and Surgeons, 8 (1), 17-22. doi: 10.4103/jhnps.jhnps_39_19

Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib

Chan, Sarah, Ahern, Elizabeth, Chaudhry, Sarah and Hughes, Brett (2019). Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib. BMJ case reports, 12 (12) e232868, e232868. doi: 10.1136/bcr-2019-232868

An update: circulating tumor cells in head and neck cancer

Kulasinghe, Arutha, Hughes, Brett G. M., Kenny, Liz and Punyadeera, Chamindie (2019). An update: circulating tumor cells in head and neck cancer. Expert Review of Molecular Diagnostics, 19 (12), 1109-1115. doi: 10.1080/14737159.2020.1688145

EGFR mutations in lung cancer: not all equal in the eyes of the immune system?

Fong, Kwun M., Hughes, Brett G. M., Lwin, Zarnie and Yang, Ian A. (2019). EGFR mutations in lung cancer: not all equal in the eyes of the immune system?. Annals of Translational Medicine, 7 (S8), S326-S326. doi: 10.21037/atm.2019.09.132

Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)

Ahern, Elizabeth, Cubitt, Annette, Ballard, Emma, Teng, Michele W. L., Dougall, William C., Smyth, Mark J., Godbolt, David, Naidoo, Rishendran, Goldrick, Amanda and Hughes, Brett G. M. (2019). Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). Trials, 20 (1) 753, 753. doi: 10.1186/s13063-019-3951-x

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, Barbara, Harrington, Kevin J, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G. M., Mesía, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Hong, Ruey-Long, González Mendoza, René, Roy, Ananya, Zhang, Yayan, Gumuscu, Burak, Cheng, Jonathan D, Jin, Fan, Rischin, Danny, Lerzo, Guillermo, Tatangelo, Marcelo, Varela, Mirta, Zarba, Juan Jose, Boyer, Michael ... Yorio, Jeffrey (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet, 394 (10212), 1915-1928. doi: 10.1016/S0140-6736(19)32591-7

Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC

Moroney, Laura B., Ward, Elizabeth C., Helios, Jennifer, Crombie, Jane, Burns, Clare L., Blake, Claire, Comans, Tracy, Chua, Benjamin, Kenny, Lizbeth and Hughes, Brett G. M. (2019). Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC. Supportive Care in Cancer, 28 (4), 1867-1876. doi: 10.1007/s00520-019-04992-x

Traveling with cancer: a guide for oncologists in the modern world

Heng, Sharon, Hughes, Brett, Hibbert, Michael, Khasraw, Mustafa and Lwin, Zarnie (2019). Traveling with cancer: a guide for oncologists in the modern world. Journal of Global Oncology, 5 (5) Y, 1-10. doi: 10.1200/JGO.19.00029

The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer

Turner, Jane, Yates, Patsy, Kenny, Lizbeth, Gordon, Louisa G., Burmeister, Bryan, Hughes, Brett G. M., McCarthy, Alexandra L., Perry, Chris, Chan, Raymond J., Paviour, Alana, Skerman, Helen, Batstone, Martin and Mackenzie, Lisa (2019). The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer. Supportive Care in Cancer, 27 (12), 4627-4637. doi: 10.1007/s00520-019-04748-7

Patterns of care for stage III non–small cell lung cancer in Australia

Parente, Phillip, Chan, Bryan A., Hughes, Brett G. M., Jasas, Kevin, Joshi, Rohit, Kao, Steven, Hegi-Johnson, Fiona, Hui, Rina, McLaughlin-Barrett, Sara, Nordman, Ina and Stone, Emily (2019). Patterns of care for stage III non–small cell lung cancer in Australia. Asia-Pacific Journal of Clinical Oncology, 15 (3), 93-100. doi: 10.1111/ajco.13140

Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma

Metaxas, Yannis, Rivalland, Gareth, Mauti, Laetitia A., Klingbiel, Dirk, Kao, Steven, Schmid, Sabine, Nowak, Anna K., Gautschi, Oliver, Bartnick, Tammo, Hughes, Brett G., Bouchaab, Hasna, Rothschild, Sacha I., Pavlakis, Nick, Wolleb, Sibylle, Petrausch, Ulf, O'Byrne, Kenneth, Froesch, Patrizia, Löffler-Baumann, Melanie, Pratsch-Peter, Susanne, Russell, Prudence, Mingrone, Walter, Savic, Spasenija, Thapa, Bibhusal, Früh, Martin, Pless, Miklos, von Moos, Roger and John, Thomas (2018). Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. Journal of Thoracic Oncology, 13 (11), 1784-1791. doi: 10.1016/j.jtho.2018.08.007

Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study

Tran, Q., Schimdt, A., Lwin, Z. and Hughes, B. G. M. (2018). Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study. Annals of Oncology, 29, viii756. doi: 10.1093/annonc/mdy424.088

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., De Castro, G., Psyrri, A., Baste Rotllan, N., Neupane, P. C., Bratland, , Fuereder, T., Hughes, B. G.M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Roy, A., Cheng, J., Jin, F. and Rischin, D. (2018). KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annals of Oncology, 29, viii729. doi: 10.1093/annonc/mdy424.045

PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma

Migden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., Lewis, K. D., Chung, C. H., Hernandez-Aya, L., Lim, A. M., Chang, A. L. S., Rabinowits, G., Thai, A. A., Dunn, L. A., Hughes, B. G. M., Khushalani, N. I., Modi, B., Schadendorf, D., Gao, B., Seebach, F., Li, S., Li, J., Mathias, M., Booth, J., Mohan, K., Stankevich, E., Babiker, H. M., Brana, I., Gil-Martin, M., Homsi, J. ... Fury, M. G. (2018). PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. New England Journal of Medicine, 379 (4), 341-351. doi: 10.1056/NEJMoa1805131

Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns

Moroney, Laura B., Helios, Jennifer, Ward, Elizabeth C., Crombie, Jane, Burns, Clare L., Yeo, Shu Qi, Pelecanos, Anita, Spurgin, Ann-Louise, Blake, Claire, Kenny, Lizbeth, Chua, Benjamin and Hughes, Brett G. M. (2018). Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns. Supportive Care in Cancer, 27 (2), 1-9. doi: 10.1007/s00520-018-4352-5

CXCR4 and PD-1 expression in head and neck cancer with perineural spread

Barnett, Catherine M., Sommerville, Ryan S., Lin, Charles, Ratnayake, Gishan, Hughes, Brett and Taheri, Touraj (2018). CXCR4 and PD-1 expression in head and neck cancer with perineural spread. Journal of Neurological Surgery, Part B: Skull Base, 80 (01), 018-022. doi: 10.1055/s-0038-1660846

Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: a prospective investigation of acute swallowing and toxicity patterns

Moroney, Laura B., Helios, Jennifer, Ward, Elizabeth C., Crombie, Jane, Pelecanos, Anita, Burns, Clare L., Spurgin, Ann-Louise, Blake, Claire, Kenny, Lizbeth, Chua, Benjamin and Hughes, Brett G. M. (2018). Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: a prospective investigation of acute swallowing and toxicity patterns. Head & Neck, 40 (9), 1955-1966. doi: 10.1002/hed.25182

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

McKeage, Mark J., Kotasek, Dusan, Markman, Ben, Hidalgo, Manuel, Millward, Michael J., Jameson, Michael B., Harris, Dean L., Stagg, Robert J., Kapoun, Ann M., Xu, Lu and Hughes, Brett G. M. (2017). Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. Targeted Oncology, 13 (1), 1-10. doi: 10.1007/s11523-017-0543-0

Clinical guidance for Radioiodine Refractory Differentiated Thyroid Cancer

Gild, Matti L., Topliss, Duncan J., Learoyd, Diana, Parnis, Francis, Tie, Jeanne, Hughes, Brett, Walsh, John P., McLeod, Donald Sa, Clifton-Bligh, Roderick J. and Robinson, Bruce G. (2017). Clinical guidance for Radioiodine Refractory Differentiated Thyroid Cancer. Clinical Endocrinology, 88 (4), 529-537. doi: 10.1111/cen.13508

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: comparison of RECIST 1.1 and RANO-HGG criteria

Gandhi, Leena, Ou, Sai-Hong Ignatius, Shaw, Alice T., Barlesi, Fabrice, Dingemans, Anne-Marie C., Kim, Dong-Wan, Camidge, D. Ross, Hughes, Brett G. M., Yang, James C. -H., de Castro, Javier, Crino, Lucio, Lena, Herve, Do, Pascal, Golding, Sophie, Bordogna, Walter, Zeaiter, Ali, Kotb, Ahmed and Gadgeel, Shirish (2017). Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: comparison of RECIST 1.1 and RANO-HGG criteria. European Journal of Cancer, 82, 27-33. doi: 10.1016/j.ejca.2017.05.019

Impact of early prophylactic feeding on long term tube dependency outcomes in patients with head and neck cancer

Brown, Teresa, Banks, Merrilyn, Hughes, Brett G. M., Lin, Charles, Kenny, Lizbeth M. and Bauer, Judith D. (2017). Impact of early prophylactic feeding on long term tube dependency outcomes in patients with head and neck cancer. Oral Oncology, 72, 17-25. doi: 10.1016/j.oraloncology.2017.06.025

Tube feeding during treatment for head and neck cancer – adherence and patient reported barriers

Brown, Teresa, Banks, Merrilyn, Hughes, Brett G. M., Lin, Charles, Kenny, Lizbeth and Bauer, Judith (2017). Tube feeding during treatment for head and neck cancer – adherence and patient reported barriers. Oral Oncology, 72, 140-149. doi: 10.1016/j.oraloncology.2017.07.017

Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities

Roberts, Kate, Culleton, Vanessa, Lwin, Zarnie, O'Byrne, Kenneth and Hughes, Brett G. M. (2017). Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities. Asia Pacific Journal of Clinical Oncology, 13 (4), 277-288. doi: 10.1111/ajco.12698

Randomised controlled trial of early prophylactic feeding vs standard care in patients with head and neck cancer

Brown, Teresa E., Banks, Merrilyn D., Hughes, Brett G. M., Lin, Charles Y., Kenny, Lizbeth M. and Bauer, Judith D. (2017). Randomised controlled trial of early prophylactic feeding vs standard care in patients with head and neck cancer. British Journal of Cancer, 117 (1), 15-24. doi: 10.1038/bjc.2017.138

A phase II trial of concurrent chemotherapy with intravenous cisplatin and vinorelbine and radiotherapy followed by consolidation chemotherapy with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the CONCAVE study

Hughes, Brett G. M., Ahern, Elizabeth, Lehman, Margot, Pratt, Gary, Dauth, Margaret, Pritchard, Wendy, Wockner, Leesa and Horwood, Keith (2017). A phase II trial of concurrent chemotherapy with intravenous cisplatin and vinorelbine and radiotherapy followed by consolidation chemotherapy with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the CONCAVE study. Asia Pacific Journal of Clinical Oncology, 13 (3), 137-144. doi: 10.1111/ajco.12649

An analysis of incidental and symptomatic pulmonary embolism (PE) in medical oncology patients

Thaker, D. A., Douglas, E., Blazak, J., Xu, W., Hughes, B., Burge, M., Steinke, K. and Wyld, D. (2017). An analysis of incidental and symptomatic pulmonary embolism (PE) in medical oncology patients. Asia-Pacific Journal of Clinical Oncology, 13 (3), 243-248. doi: 10.1111/ajco.12650

Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin

Nottage, Michelle K., Lin, Charles, Hughes, Brett G. M., Kenny, Lizbeth, Smith, David D., Houston, Kathleen and Francesconi, Alessandra (2017). Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. Head and Neck, 39 (4), 679-683. doi: 10.1002/hed.24662

Investigation of p16 status, chemotherapy regimen and other nutrition markers for predicting gastrostomy in patients with head and neck cancer

Brown, Teresa E., Wittholz, Kym, Way, Mandy, Banks, Merrilyn D., Hughes, Brett G. M., Lin, Charles Y., Kenny, Lizbeth M. and Bauer, Judith D. (2017). Investigation of p16 status, chemotherapy regimen and other nutrition markers for predicting gastrostomy in patients with head and neck cancer. Head and Neck, 39 (5), 868-875. doi: 10.1002/hed.24630

Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years

Powell, J. T., Sweeting, M. J., Ulug, P., Blankensteijn, J. D., Lederle, F. A., Becquemin, J. P., Greenhalgh, R. M., Greenhalgh, R. M., Beard, J. D., Buxton, M. J., Brown, L. C., Harris, P. L., Powell, J. T., Rose, J. D.G., Russell, I. T., Sculpher, M. J., Thompson, S. G., Lilford, R. J., Bell, P. R.F., Greenhalgh, R. M., Whitaker, S. C., Poole-Wilson, P. A., Ruckley, C. V., Campbell, W. B., Dean, M. R.E., Ruttley, M. S.T., Coles, E. C., Powell, J. T., Halliday, A. ... Chand, P. (2017). Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years. British Journal of Surgery, 104 (3), 166-178. doi: 10.1002/bjs.10430

Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT ± concurrent chemotherapy

Moroney, Laura B., Helios, Jennifer, Ward, Elizabeth C., Crombie, Jane, Wockner, Leesa F., Burns, Clare L., Spurgin, Ann-Louise, Blake, Claire, Kenny, Lizbeth and Hughes, Brett G. M. (2017). Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT ± concurrent chemotherapy. Oral Oncology, 64, 1-8. doi: 10.1016/j.oraloncology.2016.11.009

Comparison of nutritional and clinical outcomes in patients with head and neck cancer undergoing chemoradiotherapy utilizing prophylactic versus reactive nutrition support approaches

Brown, Teresa E., Banks, Merrilyn D., Hughes, Brett G. M., Lin, Charles Y., Kenny, Lizbeth M. and Bauer, Judith D. (2016). Comparison of nutritional and clinical outcomes in patients with head and neck cancer undergoing chemoradiotherapy utilizing prophylactic versus reactive nutrition support approaches. Journal of the Academy of Nutrition and Dietetics, 118 (4), 627-636. doi: 10.1016/j.jand.2016.10.013

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)

Barlesi, F., Dingemans, A. M.C., Yang, J. C.H., Ou, S. H.I., Ahn, J. S., De Petris, L., Hughes, B., Lena, H., Bordogna, W., Golding, S., Morcos, P. N., Balas, B., Zeaiter, A. and Kim, D. W. (2016). Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC). Annals of Oncology, 27 (S6), vi437. doi: 10.1093/annonc/mdw383.63

Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma

Hansen, Aaron R., Hughes, Brett G., Paul, Sanjoy, Steadman, Peter, Sommerville, Scott, Dickinson, Ian C., Walpole, Euan T., Thomson, Damien B., Mar Fan, Helen G. and Joubert, Warren L. (2016). Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma. Asia-Pacific Journal of Clinical Oncology, 12 (2), e222-e228. doi: 10.1111/ajco.12167

Alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer: a phase II global study

Ou, Sai-Hong Ignatius, Ahn, Jin Seok, De Petris, Luigi, Govindan, Ramaswamy, Yang, James Chin-Hsin, Hughes, Brett, Lena, Herve, Moro-Sibilot, Denis, Bearz, Alessandra, Ramirez, Santiago Viteri, Mekhail, Tarek, Spira, Alexander, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N., Monnet, Annabelle, Zeaiter, Ali and Kim, Dong-Wan (2016). Alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer: a phase II global study. Journal of Clinical Oncology, 34 (7), 661-668. doi: 10.1200/JCO.2015.63.9443

A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: The Australasian lung cancer trials group NITRO trial

Davidson, A., Veillard, A. -S., Tognela, A., Chan, M. M. K., Hughes, B. G. M., Boyer, M., Briscoe, K., Begbie, S., Abdi, E., Crombie, C., Long, J., Boyce, A., Lewis, C. R., Varma, S., Broad, A., Muljadi, N., Chinchen, S., Espinoza, D., Coskinas, X., Pavlakis, N., Millward, M. and Stockler, M. R. (2015). A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: The Australasian lung cancer trials group NITRO trial. Annals of Oncology, 26 (11) mdv373, 2280-2286. doi: 10.1093/annonc/mdv373

Improving guideline sensitivity and specificity for the identification of proactive gastrostomy placement in patients with head and neck cancer

Brown, Teresa E., Crombie, Jane, Spurgin, Ann-Louise, Tripcony, Lee, Keller, Jacqui, Hughes, Brett G. M., Dickie, Graeme, Kenny, Lizbeth Moria and Hodge, Robert A. (2015). Improving guideline sensitivity and specificity for the identification of proactive gastrostomy placement in patients with head and neck cancer. Head and Neck, 38 Suppl 1, 1-9. doi: 10.1002/hed.24184

Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: what makes it worthwhile?

Blinman, Prunella, Hughes, Brett, Crombie, Catherine, Christmas, Tim, Hudson, Malcolm, Veillard, Anne-Sophie, Muljadi, Nick, Millward, Michael, Wright, Gavin, Flynn, Peter, Windsor, Morgan, Stockler, Martin and Mclachlan, Sue-Anne (2015). Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: what makes it worthwhile?. European Journal of Cancer, 51 (12) 9495, 1529-1537. doi: 10.1016/j.ejca.2015.05.022

Swallowing outcomes and PEG dependence in head and neck cancer patients receiving definitive or adjuvant radiotherapy +/− chemotherapy with a proactive PEG: a prospective study with long term follow up

Crombie, Jane M., Ng, Stephanie, Spurgin, Ann-Louise, Ward, Elizabeth C., Brown, Teresa E. and Hughes, Brett G. M. (2015). Swallowing outcomes and PEG dependence in head and neck cancer patients receiving definitive or adjuvant radiotherapy +/− chemotherapy with a proactive PEG: a prospective study with long term follow up. Oral Oncology, 51 (6) 3212, 622-628. doi: 10.1016/j.oraloncology.2015.03.006

Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future

Chan, Bryan A. and Hughes, Brett G.M. (2015). Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Translational Lung Cancer Research, 4 (1), 36-54. doi: 10.3978/j.issn.2218-6751.2014.05.01

An unusual recurrence of adenosquamous carcinoma of the lung

Pokharel, Khageshwor, Godbolt, David and Hughes, Brett G. M. (2015). An unusual recurrence of adenosquamous carcinoma of the lung. Cancer Treatment Communications, 4, 37-40. doi: 10.1016/j.ctrc.2015.03.006

Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma

Foote, M. C., McGrath, M., Guminski, A., Hughes, B. G. M., Meakin, J., Thomson, D., Zarate, D., Simpson, F. and Porceddu, S. V. (2014). Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Annals of Oncology, 25 (10), 2047-2052. doi: 10.1093/annonc/mdu368

Nutrition outcomes following implementation of validated swallowing and nutrition guidelines for patients with head and neck cancer

Brown, Teresa, Ross, Lynda, Jones, Lee, Hughes, Brett and Banks, Merrilyn (2014). Nutrition outcomes following implementation of validated swallowing and nutrition guidelines for patients with head and neck cancer. Supportive Care in Cancer, 22 (9), 2381-2391. doi: 10.1007/s00520-014-2180-9

Protocol for a randomized controlled trial of early prophylactic feeding via gastrostomy versus standard care in high risk patients with head and neck cancer

Brown, Teresa, Banks, Merrilyn, Hughes, Brett, Kenny, Lizbeth, Lin, Charles and Bauer, Judith (2014). Protocol for a randomized controlled trial of early prophylactic feeding via gastrostomy versus standard care in high risk patients with head and neck cancer. BMC Nursing, 13 (1) 17, 17.1-17.10. doi: 10.1186/1472-6955-13-17

The ENHANCES study-enhancing head and neck cancer patients' experiences of survivorship: study protocol for a randomized controlled trial

Turner, Jane, Yates, Patsy, Kenny, Lizbeth, Gordon, Louisa G., Burmeister, Bryan, Thomson, Damien, Hughes, Brett, McCarthy, Alexandra L., Perry, Chris, Chan, Raymond J., Fraser, Alana, Skerman, Helen, Batstone, Martin and Carswell, Kathryn (2014). The ENHANCES study-enhancing head and neck cancer patients' experiences of survivorship: study protocol for a randomized controlled trial. Trials, 15 (1) 191. doi: 10.1186/1745-6215-15-191

Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge?

Rateesh, Shruti, Luis, Sushil A., Luis, Chris R., Hughes, Brett and Nicolae, Mugur (2014). Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge?. International Journal of Cardiology, 172 (2), E331-E333. doi: 10.1016/j.ijcard.2013.12.274

Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging

Hughes, Brett, Mileshkin, Linda, Townley, Peter, Gitlitz, Barbara, Eaton, Keith, Mitchell, Paul, Hicks, Rodney, Wood, Katie, Amler, Lucas, Fine, Bernard M., Loecke, David and Pirzkall, Andrea (2014). Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. Oncologist, 19 (2), 175-176. doi: 10.1634/theoncologist.2013-0026

Validated swallowing and nutrition guidelines for patients with head and neck cancer: Identification of high-risk patients for proactive gastrostomy

Brown, Teresa E., Spurgin, Ann-Louise, Ross, Lynda, Tripcony, Lee, Keller, Jacqui, Hughes, Brett G. M., Hodge, Rob, Walker, Quenten, Banks, Merrilyn, Kenny, Lizbeth Moira and Crombie, Jane (2013). Validated swallowing and nutrition guidelines for patients with head and neck cancer: Identification of high-risk patients for proactive gastrostomy. Head and Neck, 35 (10), 1385-1391. doi: 10.1002/hed.23146

A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma

Nowak, Anna K., Brown, Chris, Millward, Michael J., Creaney, Jenette, Byrne, Michael J., Hughes, Brett, Kremmidiotis, Gabriel, Bibby, David C., Leske, Annabell F., Mitchell, Paul L. R., Pavlakis, Nick, Boyer, Michael and Stockler, Martin R. (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma. Lung Cancer, 81 (3), 422-427. doi: 10.1016/j.lungcan.2013.05.006

Comment on 'The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer'

Kitchen, D., O'Brien, M., Hughes, B., Gill, I., Rumbles, S., Ellis, P. and Stebbing, J. (2013). Comment on 'The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer'. British Journal of Cancer, 109 (2), 526-528. doi: 10.1038/bjc.2013.279

Other novel molecular targets in non-small cell lung cancer: it's not all about EGFR

Cruikshank, Ross and Hughes, Brett (2013). Other novel molecular targets in non-small cell lung cancer: it's not all about EGFR. Cancer Forum, 37 (2), 170-174.

Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high-risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institution

Hughes, B. G. M., Jain, V. K., Brown, T., Spurgin, A. L., Hartnett, G., Keller, J., Tripcony, L., Appleyard, M. and Hodge, R. (2013). Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high-risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institution. Dysphagia, 28 (3). doi: 10.1007/s00455-013-9468-7

Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high-risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institution

Hughes, Brett G. M., Jain, Vikram K., Brown, Teresa, Spurgin, Ann-Louise, Hartnett, Gemma, Keller, Jacqui, Tripcony, Lee, Appleyard, Mark and Hodge, Robert (2013). Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high-risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institution. Head and Neck, 35 (3), 436-442. doi: 10.1002/hed.22992

Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer

Savas, Peter, Hughes, Brett and Solomon, Benjamin (2013). Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. Journal of Thoracic Disease, 5 (5), S579-S592. doi: 10.3978/j.issn.2072-1439.2013.08.52

Challenging the distal-to-proximal cannulation technique for administration of anticancer therapies: A prospective cohort study

Chan, Raymond Javan, Alexander, Alison, Bransdon, Maree, Webster, Joan, Hughes, Brett Gordon Maxwell, Brown, Leisa and Graham, Therese (2012). Challenging the distal-to-proximal cannulation technique for administration of anticancer therapies: A prospective cohort study. Cancer Nursing, 35 (5), E35-E40. doi: 10.1097/NCC.0b013e3182352916

The relationship between vitamin D and chemotherapy-induced toxicity-a pilot study

Kitchen, D., Hughes, B., Gill, I., O'Brien, M., Rumbles, S., Ellis, P., Harper, P., Stebbing, J. and Rohatgi, N. (2012). The relationship between vitamin D and chemotherapy-induced toxicity-a pilot study. British Journal of Cancer, 107 (1), 158-160. doi: 10.1038/bjc.2012.194

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

Punnoose, Elizabeth A., Atwal, Siminder, Liu, Weiqun, Raja, Rajiv, Fine, Bernard M., Hughes, Brett G. M., Hicks, Rodney J., Hampton, Garret M., Amler, Lukas C., Pirzkall, Andrea and Lackner, Mark R. (2012). Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clinical Cancer Research, 18 (8), 2391-2401. doi: 10.1158/1078-0432.CCR-11-3148

Quality-of-life among head and neck cancer survivors at one year after treatment: A systematic review

So, W. K. W., Chan, R. J., Chan, D. N. S., Hughes, B. G. M., Chair, S. Y., Choi, K. C. and Chan, C. W. H. (2012). Quality-of-life among head and neck cancer survivors at one year after treatment: A systematic review. European Journal of Cancer, 48 (15), 2391-2408. doi: 10.1016/j.ejca.2012.04.005

Medical management of mesothelioma

Bowman, Rayleen, Relan, Vandana and Hughes, Brett (2011). Medical management of mesothelioma. Australian Prescriber, 34 (5), 144-147. doi: 10.18773/austprescr.2011.076

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib

Mileshkin, Linda, Hicks, Rodney J., Hughes, Brett G. M., Mitchell, Paul L. R., Charu, Veena, Gitlitz, Barbara J., Macfarlane, David, Solomon, Benjamin, Amler, Lukas C., Yu, Wei, Pirzkall, Andrea and Fine, Bernard M. (2011). Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clinical Cancer Research, 17 (10), 3304-3315. doi: 10.1158/1078-0432.CCR-10-2763

Clinicopathological report: Bilateral choroidal metastases from papillary thyroid cancer

Tran, Khoi, Bigby, Kieron J., Hughes, Brett G., Lee, Lawrence and Allison, Roger (2011). Clinicopathological report: Bilateral choroidal metastases from papillary thyroid cancer. Asia-Pacific Journal of Clinical Oncology, 7 (1), 11-14. doi: 10.1111/j.1743-7563.2010.01332.x

Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme

Francesconi, Alessandra B., Dupre, Simon, Matos, Marco, Martin, David, Hughes, Brett G., Wyld, David K. and Lickliter, Jason D. (2010). Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. Journal of Clinical Neuroscience, 17 (8), 970-974. doi: 10.1016/j.jocn.2009.12.009

The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT

Lee, Joseph C., Hartnett, Gemma F., Hughes, Brett G.M. and Ravi Kumar, Aravind S. (2009). The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT. Nuclear Medicine Communications, 30 (5), 333-337. doi: 10.1097/MNM.0b013e32832999fa

Life-threatening interaction between complementary medicines: Cyanide toxicity following ingestion of amygdalin and vitamin C

Bromley, Jonathan, Hughes, Brett G.M., Leong, David C.S. and Buckley, Nicholas A. (2005). Life-threatening interaction between complementary medicines: Cyanide toxicity following ingestion of amygdalin and vitamin C. Annals of Pharmacotherapy, 39 (9), 1566-1569. doi: 10.1345/aph.1E634

Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): Randomized controlled trial

Greenhalgh, R. M., Brown, L. C., Epstein, D., Kwong, G. P.S., Powell, J. T., Sculpher, M. J., Thompson, S. G., Greenhalgh, R. M., Allison, D. J., Bell, P. R.F., Buxton, M. J., Harris, P. L., Hopkinson, B. R., Powell, J. T., Russell, I. T., Thompson, S. G., Brown, L. C., Barton, G., Epstein, D., Kwong, G. P.S., Macran, S., Manca, A., Reise, J. A., Williams, A., Greenhalgh, R. M., Beard, J. D., Buxton, M. J., Harris, P. L., Powell, J. T. ... Wilson, L. (2005). Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): Randomized controlled trial. The Lancet, 365 (9478), 2179-2186. doi: 10.1016/S0140-6736(05)66627-5

Docetaxel-induced myositis: Report of a novel side-effect [1]

Hughes, B. G.M. and Stuart-Harris, R. (2005). Docetaxel-induced myositis: Report of a novel side-effect [1]. Internal Medicine Journal, 35 (6), 369-370. doi: 10.1111/j.1445-5994.2005.00846.x

Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report

Hughes, Brett, Yip, Desmond, Goldstein, David, Waring, Paul, Beshay, Victoria and Chong, Guan (2004). Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report. BMC Cancer, 4 74. doi: 10.1186/1471-2407-4-74

117 High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissue signatures associated with therapy response

Kulasinghe, Arutha, Sadeghirad, Habib, Liu, Ning, Monkman, James, Tan, Chin Wee, Cooper, Caroline, Church, Sarah, Schneider, Fabian, Thaagard, Jeppe, Mansfield, James, O’byrne, Kenneth, Davis, Melissa and Hughes, Brett (2022). 117 High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissue signatures associated with therapy response. LONDON: BMJ Publishing Group Ltd. doi: 10.1136/jitc-2022-sitc2022.0117

Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)

Grob, Jean-Jacques, Gonzalez, Rene, Basset-Seguin, Nicole, Vornicova, Olga, Schachter, Jacob, Joshi, Abhishek, Meyer, Nicolas, Grange, Florent, Piulats, Josep M., Bauman, Jessica R., Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F. and Hughes, Brett G. M. (2020). Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). European Society for Medical Oncology Annual Meeting, Barcelona, Spain, 27 September - 1 October 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.19.03054

Abstract 3384: characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancer

Kulasinghe, Arutha, Kapeleris, Joanna, Kenny, Liz, Hughes, Brett, Warkiani, Majid, Vela, Ian, Thiery, Jean-Paul, O'Byrne, Ken and Punyadeera, Chamindie (2020). Abstract 3384: characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancer. AACR Annual Meeting 2020, Philadelphia, PA USA, 27-28 April 2020 and 22-24 June 2020. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/1538-7445.am2020-3384

Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC)

O'Leary, Connor, Fletcher, James, Yuile, Alexander, Xu, Wen, Ladwa, Rahul, McGrath, Margaret, Pavlakis, Nick, Hughes, Brett, McCaffery, Elizabeth and O'Byrne, Kenneth (2020). Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC). Medical Oncology Group of Australia Annual Scientific Meeting, Virtual, Australia, 14-21 August 2020. Chichester, West Sussex, United Kingdom: Wiley-Blackwell.

Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC)

Rischin, D., Khushalani, N. I., Schmults, C. D., Guminski, A., Chang, A. L. S., Lewis, K. D., Lim, A. M., Hernandez-Aya, L., Hughes, B. G. M., Schadendorf, D., Hauschild, A., Stankevich, E., Booth, J., Li, S., Chen, Z., Desai, J., Lowy, I., Fury, M. G. and Migden, M. R. (2019). Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC). Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva Switzerland, Dec 11-14, 2019. OXFORD: OXFORD UNIV PRESS.

Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study

Grob, J. J., Gonzalez Mendoza, R., Basset-Seguin, N., Vornicova, O., Schachter, J., Joshi, A., Meyer, N., Grange, F., Piulats, J. M., Bauman, J., Zhang, P., Gumuscu, B., Swaby, R. F. and Hughes, B. G. M. (2019). Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona Spain, Sep 27-Oct 01, 2019. OXFORD: OXFORD UNIV PRESS.

Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)

Rischin, D., Lim, A. M., Schmults, C. D., Khushalani, N. I., Hughes, B. G., Schadendorf, D., Dunn, L. A., Chang, A. L. S., Hauschild, A., Ulrich, C., Eigentler, T., Migden, M. R., Pavlick, A. C., Geiger, J., Stankevich, E., Li, S., Lowy, I., Fury, M. G. and Guminski, A. (2019). Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC). 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 1 October 2019. Oxford, United Kingdom: Oxford University Press.

KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma

Grob, Jean-Jacques, Gonzalez Mendoza, Rene, Basset-Seguin, Nicole, Schachter, Jacob, Vornicova, Olga, Bauman, Jessica, Grange, Florent, Meyer, Nicolas, Piulats, Josep, Zhang, Pingye (Eric), Gumuscu, Burak, Swaby, Ramona and Hughes, Brett G. M. (2019). KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma. AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology, Atlanta Ga, Mar 29-Apr 03, 2019. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. doi: 10.1158/1538-7445.AM2019-CT170

Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN)

Ahern, Elizabeth Stephanie, Cubitt, Annette, Ballard, Emma, Teng, Michele W.L., Dougall, William C., Smyth, Mark J. and Hughes, Brett Gordon Maxwell (2019). Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN). 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA United States, 28 February — 2 March 2019. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2019.37.8_suppl.tps129

Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FOG-PET staging

Senko, Clare, Moore, Julie, Hay, Karen, Lwin, Zarnie, Pratt, Gary, Fong, Kwun and Hughes, Brett Gordon Maxwell (2019). Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FOG-PET staging. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology.

Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC)

Wirth, Lori J., Leboulleux, Sophie, Kiyota, Naomi, Tahara, Makoto, Muro, Kei, Ahn, Myung-Ju, Ando, Yuichi, Taylor, Matthew H., Takahashi, Shunji, Kim, Sung-Bae, Misir, Soamnauth, Dutcus, Corina E., Xie, Ran, Joshi, Prashant Ramesh, Hughes, Brett Gordon Maxwell, Aller, Javier, Krzyzanowska, Monika K. and Capdevila, Jaume (2019). Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.6081

KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC)

Grob, Jean Jacques, Gonzalez, Rene, Basset-Seguin, Nicole, Schachter, Jacob, Vornicova, Olga, Bauman, Jessica Ruth, Grange, Florent, Meyer, Nicolas, Piulats, Josep M., Zhang, Eric (Pingye), Gumuscu, Burak, Swaby, Ramona F. and Hughes, Brett Gordon Maxwell (2019). KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.TPS9598

Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up

Guminski, Alexander David, Lim, Annette May Ling, Khushalani, Nikhil I., Schmults, Chrysalyne D., Hernandez-Aya, Leonel Fernando, Modi, Badri, Dunn, Lara, Hughes, Brett Gordon Maxwell, Chang, Anne Lynn S., Hauschild, Axel, Migden, Michael Robert, Gutzmer, Ralf, Alam, Murad, Jankovic, Vladimir, Stankevich, Elizabeth, Booth, Jocelyn, Li, Siyu, Lowy, Israel, Fury, Matthew G. and Rischin, Danny (2019). Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 Jun 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.9526

Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Rischin, Danny, Harrington, Kevin J., Greil, Richard, Soulieres, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Baste, Neus, Neupane, Prakash C., Bratland, Ase, Fuereder, Thorsten, Hughes, Brett Gordon Maxwell, Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Zhang, Yayan, Jin, Fan, Gumuscu, Burak and Burtness, Barbara (2019). Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 Jun 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.6000

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., De Castro, G., Psyrri, A., Rotllan, N. Baste, Neupane, P. C., Bratland, A., Fuereder, T., Hughes, B. G. M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Ishak, W. Z. Wan, Roy, A., Cheng, J., Jin, F. and Rischin, D. (2018). KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS.

Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer

Itchins, M., Alexander, M., John, T., Kao, S., Hughes, B., Hayes, S., Howel, V., Harvie, R., Clarke, S., Millward, M. and Pavlakis, N. (2018). Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jtho.2018.08.1104

BR-34-randomized trial of durvalumab and tremelimumab +/- platinum chemotherapy in patients with metastatic squamous or non-squamous NSCLC

Kulkarni, S., Laurie, S., Goss, G., Perrone, F., Hughes, B., Pavlakis, N., Stockler, M., Blais, A., Zibdawi, L., Vera-Badillo, F. and Leighl, N. (2018). BR-34-randomized trial of durvalumab and tremelimumab +/- platinum chemotherapy in patients with metastatic squamous or non-squamous NSCLC. IASLC 19th World Conference on Lung Cancer, Toronto, Canada, 23-26 September 2018. New York, NY USA: Elsevier. doi: 10.1016/j.jtho.2018.08.608

Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer

Ratnayake, G., Shankar, M., Roberts, K., Mason, R., Hughes, B. G. M., Lwin, Z., Jain, V., O'Byrne, K. J. and Chua, B. (2018). Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer. 43rd ESMO Congress (ESMO), Munich, Germany, 19-23 October 2018. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mdy292.093

Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel in 1L advanced squamous NSCLC

Socinski, M. A., Rittmeyer, A., Shapovalov, D., Orlandi, F., McCleod, M., Soo, R. A., Palmero, R., Kozuki, T., Migliorino, M. R., Koynov, K. D., Berard, H., Hughes, B. G. M., Yu, W., Graupner, V., Sun, S. W., Kowanetz, M., Hoang, T., Lin, W. and Jotte, R. M. (2018). Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel in 1L advanced squamous NSCLC. 43rd ESMO Congress, Munich, Germany, 19-23 October 2018. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mdy424.077

Outcomes of Nivolumab in Metastatic NSCLC Patients via the Access Program Across Multiple Tertiary Oncology Centers

Roberts, K., Mason, R., Hughes, B., Lwin, Z., Jain, V. and O'Byrne, K. (2017). Outcomes of Nivolumab in Metastatic NSCLC Patients via the Access Program Across Multiple Tertiary Oncology Centers. HOBOKEN: WILEY.

Pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH)

Mauti, L., Rivalland, G., Klingbiel, D., Kao, S., Schmid, S., Nowak, A., Gautschi, O., Hughes, B., Bartnick, T., Pavlakis, N., Bouchaab, H., O'Byrne, K., Rothschild, S., Russell, P., Savic Prince, S., Thapa, B., Pless, M., von Moos, R., Metaxas, Y. and John, T. (2017). Pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH). ESMO Immuno Oncology Congress 2017, Geneva, Switzerland, 7–10 December 2017. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mdx711.007

Lean Thinking: Exploring Overhead and Supplementary Tasks (Ost) in Cancer Care (Cc) in the Oncology Outpatient Encounter (Ooe)

Peters, G., Smith, D., Rasool, M., Ladwa, R., Hughes, B. and Lwin, Z. (2016). Lean Thinking: Exploring Overhead and Supplementary Tasks (Ost) in Cancer Care (Cc) in the Oncology Outpatient Encounter (Ooe). HOBOKEN: WILEY-BLACKWELL.

The Significance of Pulmonary Nodules in Head and Neck Cancer

Ladwa, R., Xu, W., Tani, D., Wockener, L., Williamson, K., Lwin, Z., Ritchie, A., Steinke, K. and Hughes, B. (2016). The Significance of Pulmonary Nodules in Head and Neck Cancer. HOBOKEN: WILEY-BLACKWELL.

Nutrition Outcomes and Toxicities Following Helical-Intensity Modulated Radiotherapy (H-Imrt) in Patients with Head and Neck Cancer

Blake, Claire, Lai, Rainbow, Moroney, Laura, Helios, Jennifer, Hughes, Brett, Chua, Ben, Bauer, Judy and Brown, Teresa (2016). Nutrition Outcomes and Toxicities Following Helical-Intensity Modulated Radiotherapy (H-Imrt) in Patients with Head and Neck Cancer. COSA's 43rd and ANZBCTG's 38th Annual Scientific Meetings. Partners for Progress in Breast Cancer Research and Care, Gold Coast, QLD, Australia, 15-17 November 2016. Chichester, West Sussex United Kingdom: Wiley.

Pneumocystis pneumonia (Pjp) in lung cancer patients

Chavalertsakul, Nuttaya, Lwin, Zarnie, Hay, Karen and Hughes, Brett (2016). Pneumocystis pneumonia (Pjp) in lung cancer patients. COSA's 43rd and ANZBCTG's 38th Annual Scientific Meetings. Partners for Progress in Breast Cancer Research and Care, Gold Coast, QLD Australia, 15-17 November 2016. HOBOKEN: WILEY-BLACKWELL.

Understanding Initiation of Nutrition Support in Patients with Head and Neck Cancer (Hnc) and Adherence to Recommendations-A Patient Perspective

Brown, Teresa, Banks, Merrilyn, Hughes, Brett, Lin, Charles, Kenny, Lizbeth and Bauer, Judith (2016). Understanding Initiation of Nutrition Support in Patients with Head and Neck Cancer (Hnc) and Adherence to Recommendations-A Patient Perspective. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing.

The Wau (weighted activity unit) effect: evaluating the cost of Drg (Diagnosis related group) coding

Tan, J. Y., Bennett, R., Power, J., Thompson, L., Hughes, B. and Lwin, Z. (2015). The Wau (weighted activity unit) effect: evaluating the cost of Drg (Diagnosis related group) coding. The Medical Oncology Group of Australia 2015 ASM, Pathways in Medical Oncology – The Path Less Travelled, Hobart, Australia, 5‐7 August 2015. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing.

Single Agent Panitumumab in Patients With Incurable Cutaneous Squamous Cell Carcinoma: A Single-Center Phase 2 Study

Porceddu, S., Foote, M., McGrath, M., Guminski, A., Hughes, B., Meakin, J., Thomson, D., Thomson, D. and Simpson, F. (2014). Single Agent Panitumumab in Patients With Incurable Cutaneous Squamous Cell Carcinoma: A Single-Center Phase 2 Study. ELSEVIER SCIENCE INC. doi: 10.1016/j.ijrobp.2013.11.179

Single agent panitumumab in patients with incurable cutaneous squamous cell carcinoma: A single centre phase II study

Foote, M., McGrath, M., Guminski, A., Hughes, B., Meakin, J., Thomson, D., Simpson, F. and Porceddu, S. (2013). Single agent panitumumab in patients with incurable cutaneous squamous cell carcinoma: A single centre phase II study. 17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity, Amsterdam Netherlands, Sep 27-Oct 01, 2013. Oxford United Kingdom: Pergamon Press. doi: 10.1016/S0959-8049(13)70065-0

Pulmonary Embolism in Medical Oncology Patients: Symptomatic Versus Incidental

Thaker, D. A., Blazak, J., Wyld, D., Steinke, K., Hughes, B. and Burge, M. (2012). Pulmonary Embolism in Medical Oncology Patients: Symptomatic Versus Incidental. HOBOKEN: WILEY-BLACKWELL.

Safety of bevacizumab used in routine practice in patients with metastatic colorectal cancer

Dzienis, M., Malczewski, A., Goh, J., Hughes, B., Eastgate, M., Wyld, D. and Burge, M. (2012). Safety of bevacizumab used in routine practice in patients with metastatic colorectal cancer. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting, Brisbane, QLD Australia, 8-10 August 2012. Wiley-Blackwell Publishing.

Challenging the distal-to-proximal technique in the administration of anti-cancer therapies: A prospective cohort study

Alexander, Alison, Chan, Raymond, Bransdon, Maree, Hughes, Brett, Brown, Leisa and Graham, Therese (2011). Challenging the distal-to-proximal technique in the administration of anti-cancer therapies: A prospective cohort study. The 20th annual RBWH Health Care Symposium: Personalised Health Care, Herston, Brisbane, QLD, Australia, 10-14 October 2011.

The lung cancer journey - a review from the prince charles hospital pulmonary malignancy unit

Rassam, L. J., Sinhal, N. P., Mackenzie, H., Bowman, R. V., Fong, K. M., Yang, I. A., Pratt, G., Fay, M., Hughes, B., Windsor, M. F. and Matar, K. (2011). The lung cancer journey - a review from the prince charles hospital pulmonary malignancy unit. 3rd Australian Lung Cancer Conference (ALCC), Melbourne VIC, Australia, 6-8 October 2011. Philadelphia PA, United States: Lippincott Willams & Wilkins. doi: 10.1097/01.JTO.0000394634.73009.dc